AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots

BenevolentAI said it will still develop its internally discovered drugs, but will now seek partners for them earlier in their development. Going forward, BenevolentAI will focus on making its AI technologies available to support the drug R&D efforts of its partners. The post AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio…

Endobronchial Valves Help Advanced COPD and Emphysema Patients Breathe Easier

Patients who were previously facing challenges like needing oxygen after just a few steps or struggling with breathlessness from simple movements are finding new possibilities for daily life. The post Endobronchial Valves Help Advanced COPD and Emphysema Patients Breathe Easier appeared first on MedCity News.

More Than 70 Organizations Urge Congress to Extend Enhanced Premium Tax Credits

In a letter, Families USA and numerous other organizations called on Congress to extend the enhanced premium tax credits that are set to expire at the end of 2025. The post More Than 70 Organizations Urge Congress to Extend Enhanced Premium Tax Credits appeared first on MedCity News.

Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages

Arcellx’s cell therapy for multiple myeloma has shown no signs of the parkinsonism complication observed in clinical testing of Carvykti, a rival product from partners Johnson & Johnon and Legend Biotech. Arcellx is developing its CAR T-treatment under a partnership with Gilead Sciences. The post Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But…

Consumer Empowerment Closes Medicaid Member Care Gaps

While enrollment in consumer direction programs has grown, more must be done to educate, amplify, and spread awareness to ensure that all eligible individuals learn about the benefits of this alternative to traditionally delivered agency and institutional care. The post Consumer Empowerment Closes Medicaid Member Care Gaps appeared first on MedCity News.

GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH

Results from the Phase 3 DREAMM-7 study show GSK drug Blenrep is helping multiple myeloma patients live longer compared to treatment with blockbuster Johnson & Johnson drug Darzalex. The data, presented Monday during the annual meeting of the American Society of Hematology, are part of a submission now under FDA review that could lead to…